EXHIBIT 99.1 Summary of Consolidated Financial Statements and Notes as of December 31, 2023 Consolidated Statements of Financial Position (in thousand euros) | | December 31, 2023 | December 31, 2022 | | --- | --- | --- | | Assets | | | | Cash and cash equivalents | 70,605 | 84,225 | | Short-term investments | 21,851 | 17,260 | | Trade receivables and others - current | 55,557 | 38,346 | | Total current assets | 148,012 | 139,831 | | Intangible assets | 416 | 1,556 | | Property and equipment | 6,322 | 8,542 ...

Company Participants Ashiq Mubarack - Citi Jingming Chen - Evercore ISI Daina Graybosch - Leerink Partners I'd now like to welcome Henry Wheeler to begin the conference. Henry, over to you. On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Mondher Mahjoubi I ...

The following interim condensed consolidated financial statements have been approved by the Executive Board of the Company on September 13, 2023, and have been subject to a limited review by our Statutory Auditors. They have been examined by the Supervisory Board of the Company on September 13, 2023. INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2023 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,026,535.85 euros composed of ...

Disclaimer on Forward-Looking Information and Risk Factors This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to i statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertairi cause the Company's actual results or financial condition to differ materially from those anticipated. Thes ...

Company Participants Ashiq Mubarack - Citigroup Daina Graybosch - SVB Securities Swayampakula Ramakanth - H.C. Wainwright & Co. Justine Telliez - Kepler Cheuvreux Jingming Chen - Evercore ISI Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year todate as well as addressing future goals and milestones. The press release and today's presentation are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of April 2023 Commission File Number: 001-39084 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Re ...

Europe Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models. | --- | --- | --- | --- | --- | --- | --- | --- | |------------------|----------------------|--------|-----------------------------------|----------------|-------|-----------------------|----------------| | | | | | | | | | | | IPH6101/SAR'579 | | IPH6401/SAR'514 | IPH62 | | OPTION | | | Ongoing programs | CD123 Phase 1 in AML | | Progression towards IND | B7-H3 Research | | 2 undisclosed targets | ...

Financial Data and Key Metrics Changes - The revenue and other income amounted to €57.7 million, primarily from collaboration and licensing agreements and governmental funding [70] - Operating expenses were €74.1 million, a 1% increase compared to 2021, while R&D expenses rose by 10% to €51.7 million due to clinical and nonclinical research [71] - Cash and cash equivalents stood at €136.6 million as of December 31, 2022, with an additional €25 million payment from Sanofi expected to be added [51][52] Business Line Data and Key Metrics Changes - The company is focusing on its lead product candidate, lacutamab, which is in development for T cell lymphoma, with final readouts expected in the second half of 2023 [9][21] - The ANKET platform continues to progress, with Sanofi signing a second deal, and multiple programs in early development [11][39] - Monalizumab is advancing in Phase 3 trials for lung cancer, with AstraZeneca leading the efforts [12][25] Market Data and Key Metrics Changes - The company is expanding its presence in the NK cell space, leveraging its antibody engineering capabilities to develop innovative molecules [18][36] - The partnership with AstraZeneca for monalizumab is expected to yield significant milestones, with a total package of up to $1.275 billion [34] Company Strategy and Development Direction - The company aims to create near-term value through its proprietary product candidate lacutamab and to build a sustainable foundation through various partnerships [8][19] - The focus remains on maximizing the value of its products while advancing its R&D engine to create a sustainable business [10][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and partnerships, highlighting the importance of upcoming data readouts over the next 24 months [44][93] - The company is strategically managing resources to ensure continued investment in its vision and pipeline [40][55] Other Important Information - The company has received Fast Track designation for lacutamab in the U.S. and PRIME designation in the EU, indicating regulatory support for its development [29] - The company is exploring ADC technology alongside its ANKET platform, indicating a diversified approach to drug development [63] Q&A Session Summary Question: Can you elaborate on the registrational pathway for mycosis fungoides? - Management indicated that they are keeping options open for a complete registration trial on mycosis fungoides or a combination with Sézary syndrome, ensuring alignment with regulators [58][60] Question: Where does the linker payload technology for the ADC program come from? - The company confirmed that they have selected a development candidate for the ADC program IPH4501 and will provide updates later in the year [61] Question: What changes have occurred in the guidance for outcomes in CTCL? - Management noted that there have been clarifications in the guidance, and they will provide more details in upcoming calls [64][79] Question: Can you provide more details on the inclusion and exclusion criteria for the COMBO study? - The monotherapy trial is focused on KIR3DL2 positive patients with no maximum lines of therapy, while the COMBO study includes a comparator arm with chemotherapy [82][96] Question: How should we think about costs in 2023? - Management indicated that the cash burn for 2023 will be in the same range or slightly lower than previous years, allowing for funding of new studies without increasing costs [101]

Exhibit 99.1 Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update MARSEILLE, France--(BUSINESS WIRE)--March 23, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release. "In 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a ...